-
Product Insights
Relapsed Multiple Myeloma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Relapsed Multiple Myeloma Clinical Trial Report Overview A total of 1702 relapsed multiple myeloma clinical trials were conducted as of November 2024. The relapsed multiple myeloma clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      Asia-Pacific ·      ...
-
Product Insights
Refractory Multiple Myeloma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Refractory Multiple Myeloma Clinical Trial Report Overview A total of 1726 refractory multiple myeloma clinical trials were conducted as of November 2024. The refractory multiple myeloma clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      Asia-Pacific ·      ...
-
Sector Analysis
Multiple Myeloma Epidemiology Analysis and Forecast to 2032
Multiple Myeloma Epidemiology Analysis Report Overview In the 8MM, there were 80,305 diagnosed incident cases of multiple myeloma in 2022. The diagnosed incident cases of multiple myeloma are expected to register an AGR of more than 1% during 2022-2032. Multiple myeloma (MM) is a hematologic cancer that forms in a type of white blood cell called plasma cells. Normal plasma cells help fight infections by making antibodies that recognize and attack germs, but MM causes cancer cells to accumulate in...
-
Product Insights
Multiple Myeloma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Multiple Myeloma Clinical Trials Market Overview The Multiple Myeloma (Kahler Disease) clinical trial market research report provides an overview of Multiple Myeloma (Kahler Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Sector Analysis
Multiple Myeloma - Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Multiple Myeloma Cell Therapy Market Report Overview The total market value for the 15M, which includes both cell therapies and established/traditional MM therapies was $25.7 billion in 2021. The following are some of the key highlights of the multiple myeloma cell therapy market: The market growth will be attributed to the established CAR-T agents such as Abecma and Carvykt. The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.